Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.51 |
| ▸ | HTR6 | P50406 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | PTGDR2 | Q9Y5Y4 | 10/20 | 0.46 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6541353 | 0.86 | HTR6 (0.51) | HTR6TSHRALDH1A1PTGDR2PTPN1 | |
| SCHEMBL6540045 | 0.85 | APEX1 (0.51) | HTR6ALDH1A1PTGDR2PTPN1 | |
| SCHEMBL6540959 | 0.82 | TDP1 (0.48) | TDP1TSHRALDH1A1PTGDR2PTPN1 | |
| SCHEMBL6552312 | 0.81 | HTR6 (0.48) | HTR6TSHRGLASMN1; SMN2 | |
| SCHEMBL6552306 | 0.81 | HTR6 (0.47) | HTR6TSHRALDH1A1CYP2C19GLA | |
| SCHEMBL6540943 | 0.80 | ALDH1A1 (0.73) | HTR6TSHRALDH1A1 | |
| SCHEMBL6541275 | 0.80 | PTPN1 (0.47) | TDP1TSHRALDH1A1PTGDR2PTPN1 | |
| SCHEMBL20915127 | 0.79 | TDP1 (0.62) | TDP1TSHRPTGDR2PTPN1CYP2C19 | |
| SCHEMBL6554461 | 0.78 | HTR6 (0.56) | HTR6TSHRSMN1; SMN2 | |
| SCHEMBL6540377 | 0.78 | ALDH1A1 (0.61) | ALDH1A1PTGDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040138462-A1 | Aminoalcohol derivatives | ASTELLAS PHARMA INC. (JP) | 2004-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138462-A1 | Aminoalcohol derivatives | BPHL, FANCD2, HRH2 | TDP1 1972/4885HTR6 522/4885TSHR 3667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.